MLchartDataset catalogue

AIE regimen

Term · Oncology and biomedicine · MLC-T-ONC-009734

A regimen consisting of cytarabine (Ara-C), idarubicin and etoposide, used as an induction treatment for pediatric acute myeloid leukemia (AML). High-dose cytarabine/etoposide/idarubicin regimen may be used for the treatment of AML.

Table 1. Record
IdentifierMLC-T-ONC-009734
FieldOncology and biomedicine
AbbreviationAIE
SynonymsAraC-idarubicin-etoposide regimen; cytarabine-idarubicin-etoposide regimen; MRC AML10 study-AIE regimen
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-009734",
  "term": "AIE regimen",
  "field": "Oncology and biomedicine",
  "definition": "A regimen consisting of cytarabine (Ara-C), idarubicin and etoposide, used as an induction treatment for pediatric acute myeloid leukemia (AML). High-dose cytarabine/etoposide/idarubicin regimen may be used for the treatment of AML.",
  "abbreviation": "AIE",
  "synonyms": [
    "AraC-idarubicin-etoposide regimen",
    "cytarabine-idarubicin-etoposide regimen",
    "MRC AML10 study-AIE regimen"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/aie-regimen/"
}

Record 569 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.